Published in Mod Pathol on May 01, 2015
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. J Clin Oncol (2016) 0.77
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat (2017) 0.75
Estimating the OncotypeDX score: validation of an inexpensive estimation tool. Breast Cancer Res Treat (2016) 0.75
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol (2011) 4.70
Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst (2004) 4.57
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer (1983) 3.94
Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol (2008) 3.89
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem (2007) 3.05
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol (2007) 2.24
Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol (2008) 1.72
Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer (1984) 1.71
Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol (2008) 1.69
Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed? Breast J (2013) 1.51
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat (2013) 1.49
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat (2011) 1.47
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst (2012) 1.42
The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol (2012) 1.37
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer (2010) 1.34
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol (2013) 1.23
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat (2008) 1.12
Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol (2012) 1.07
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ (2012) 1.06
Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol (2011) 1.05
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer (2011) 1.02
A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Pathol (2011) 1.02
Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol (2012) 1.01
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest (2010) 1.00
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med (2009) 0.99
HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol (2008) 0.99
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat (2013) 0.97
The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem (2011) 0.96
Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved. Ann Oncol (2014) 0.94
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol (2008) 0.93
Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med (2010) 0.92
Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases. Appl Immunohistochem Mol Morphol (2013) 0.92
Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS Curr (2011) 0.91
[Cost-effectiveness of a chemotherapy predictive test]. Bull Cancer (2012) 0.88
Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score. Appl Immunohistochem Mol Morphol (2013) 0.88
Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med (2008) 0.86
Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol (2012) 0.86
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation. Breast J (2013) 0.84
Pathological work up of the primary tumor: getting the proper information out of it. Breast (2011) 0.81
Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers? Am Surg (2011) 0.81
Precision oncology in breast cancer: better than ever, or less than before? Breast J (2013) 0.76
Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. Support Care Cancer (2017) 0.75
Targeted therapies in breast cancer: tailoring treatment to the molecular drivers of disease progression. MLO Med Lab Obs (2012) 0.75